#1 Clinical Trials Search in Europe

Elritercept

Elritercept, also known as KER-050, is an investigational drug being studied in clinical trials for the treatment of myelofibrosis (MF) and myelodysplastic syndromes (MDS). These trials aim to evaluate the safety, tolerability, and efficacy of elritercept in patients with anemia associated with these blood disorders. The studies are exploring elritercept as both a monotherapy and in combination with other treatments, offering hope for improved outcomes in patients with these challenging conditions.

Table of Contents

What is Elritercept?

Elritercept, also known as KER-050, is an investigational drug being developed for the treatment of certain blood disorders[1]. It is a novel protein therapeutic that consists of a modified activin receptor type-2A extracellular domain fused to a human IgG1 Fc domain[2]. This unique structure allows elritercept to potentially address multiple aspects of blood cell production.

Conditions Treated

Elritercept is being studied for the treatment of two main conditions:

  1. Myelofibrosis (MF): A rare bone marrow cancer that disrupts the body’s normal production of blood cells[1]. There are three types being studied:
    • Primary myelofibrosis (PMF)
    • Post-essential thrombocythemia myelofibrosis (post-ET MF)
    • Post-polycythemia vera myelofibrosis (post-PV MF)
  2. Myelodysplastic Syndromes (MDS): A group of disorders characterized by ineffective production of blood cells, leading to low blood cell counts[2]. The study focuses on patients with very low, low, or intermediate-risk MDS.

How It Works

Elritercept is designed to promote the production of red blood cells and potentially other blood cell types. It works by modulating the activity of certain proteins in the TGF-β superfamily, which play a crucial role in regulating blood cell formation[1]. By targeting these pathways, elritercept aims to improve blood cell production and alleviate symptoms associated with MF and MDS, particularly anemia (low red blood cell count).

Administration

Elritercept is administered as a subcutaneous injection, which means it is injected just under the skin[1][2]. The dosage and frequency of administration are still being determined through clinical trials.

Clinical Trials

Elritercept is currently being evaluated in two main clinical trials:

  1. Myelofibrosis Study: A Phase 2 open-label study evaluating elritercept alone or in combination with ruxolitinib (another medication used to treat MF) in patients with myelofibrosis and anemia[1].
  2. Myelodysplastic Syndromes Study: A Phase 2 open-label, ascending dose study of elritercept for the treatment of anemia in patients with very low, low, or intermediate-risk MDS[2].

These trials aim to assess the safety, tolerability, and effectiveness of elritercept in treating these conditions.

Potential Benefits

The potential benefits of elritercept being investigated include:

  • Improvement in anemia and reduction in the need for blood transfusions[1][2]
  • Alleviation of symptoms associated with MF and MDS
  • Potential improvement in overall quality of life for patients
  • Possible reduction in spleen volume for MF patients[1]

Safety and Side Effects

As elritercept is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for any adverse events or side effects[1][2]. Patients participating in these trials are carefully screened and monitored throughout the study period.

Conclusion

Elritercept represents a promising new approach to treating myelofibrosis and myelodysplastic syndromes, particularly for patients suffering from anemia. While the results of the ongoing clinical trials are eagerly awaited, it’s important to remember that elritercept is still an investigational drug. Patients interested in this treatment should discuss it with their healthcare providers and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name Elritercept (KER-050)
Conditions Studied Myelofibrosis (MF) and Myelodysplastic Syndromes (MDS)
Administration Subcutaneous injection
Trial Phases Phase 2
Main Objectives Evaluate safety, tolerability, and efficacy in treating anemia
Key Eligibility Criteria Adult patients with MF or MDS, specific anemia criteria, ECOG status ≤2
Primary Endpoints Incidence of adverse events, safety, and tolerability
Secondary Endpoints Efficacy in treating anemia, pharmacokinetics, effect on disease progression
Study Design Open-label, dose escalation and expansion

FAQ

  • What is elritercept? Elritercept, also known as KER-050, is an investigational drug being studied for the treatment of anemia in patients with myelofibrosis (MF) and myelodysplastic syndromes (MDS). It is a protein-based medication that targets specific receptors involved in blood cell production.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on myelofibrosis (MF) and myelodysplastic syndromes (MDS). These are blood disorders that can cause anemia and other blood-related problems.
  • How is elritercept administered in these trials? Elritercept is administered as a subcutaneous injection, which means it is given as a shot under the skin.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety, tolerability, and effectiveness of elritercept in treating anemia associated with MF and MDS. The studies also aim to determine the best dosage and assess how the drug affects blood cell production.
  • Who can participate in these clinical trials? Eligibility varies, but generally, adult patients with diagnosed MF or MDS who have anemia and meet specific criteria regarding their disease status, previous treatments, and overall health may be eligible to participate. However, there are also several exclusion criteria that might prevent some patients from participating.

Ongoing Clinical Trials on Elritercept

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Greece Hungary +8

  • Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

    Recruiting

    3 1
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Ireland +5

  • Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Spain

Glossary

  • Myelofibrosis (MF): A rare blood cancer where the bone marrow is replaced by scar tissue, leading to problems with blood cell production.
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.
  • Anemia: A condition where you don't have enough healthy red blood cells to carry adequate oxygen to your body's tissues.
  • Elritercept (KER-050): An investigational drug being studied for the treatment of anemia in MF and MDS patients.
  • Subcutaneous injection: A method of giving medication by injecting it under the skin.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Efficacy: The ability of a treatment to produce the desired result.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Hemoglobin (Hgb): A protein in red blood cells that carries oxygen throughout the body.
  • Red blood cell (RBC) transfusion: A procedure where red blood cells are given to a person through an intravenous (IV) line into the blood vessels.

References

  1. http://clinicaltrials.eu/trial/study-on-ker-050-and-ruxolitinib-for-patients-with-myelofibrosis-and-anemia/
  2. http://clinicaltrials.eu/trial/study-of-elritercept-for-treating-anemia-in-patients-with-low-to-intermediate-risk-myelodysplastic-syndromes-mds/